1. Home
  2. SLNH vs BCDA Comparison

SLNH vs BCDA Comparison

Compare SLNH & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soluna Holdings Inc.

SLNH

Soluna Holdings Inc.

HOLD

Current Price

$1.53

Market Cap

174.8M

Sector

Technology

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.27

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLNH
BCDA
Founded
1961
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.8M
14.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLNH
BCDA
Price
$1.53
$1.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$25.00
AVG Volume (30 Days)
5.4M
67.0K
Earning Date
11-17-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$28,782,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$45.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$1.00
52 Week High
$5.14
$3.20

Technical Indicators

Market Signals
Indicator
SLNH
BCDA
Relative Strength Index (RSI) 44.18 41.88
Support Level $1.25 $1.23
Resistance Level $1.65 $1.34
Average True Range (ATR) 0.23 0.08
MACD 0.02 -0.01
Stochastic Oscillator 27.88 17.86

Price Performance

Historical Comparison
SLNH
BCDA

About SLNH Soluna Holdings Inc.

Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: